Can you take Saxagliptin with Sevabertinib?
1 drug interaction and 8 additional warnings found for the following 2 drugs:
- saxagliptin
- sevabertinib
Drug interactions
Moderate drug interactions
Moderate:
sAXagliptin sevabertinib
Applies to: saxagliptin and sevabertinib
Sevabertinib may increase the blood levels of sAXagliptin. In some cases, this can increase the risk and/or severity of side effects such as hypoglycemia, or low blood sugar.
Symptoms of hypoglycemia include:
- headache
- dizziness
- drowsiness
- nervousness
- weakness
- tremor
- nausea
- hunger
- sweating
- fast or pounding heartbeats
You may need a dose adjustment or more frequent monitoring of your blood sugar to safely use both medications.
It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Food/lifestyle interactions
Moderate food/lifestyle interactions
Moderate:
sAXagliptin Food/Lifestyle
Applies to: saxagliptin
Alcohol may affect blood glucose levels in patients with diabetes. Both hypoglycemia (low blood sugar) and hyperglycemia (high blood sugar) may occur, depending on how much and how often you drink.
You should avoid using alcohol if your diabetes is not well controlled or if you have:
- high triglycerides
- neuropathy (nerve damage)
- pancreatitis
Moderate alcohol consumption generally does not affect blood glucose levels if your diabetes is under control. However, it may be best to limit alcohol intake to one drink daily for women and two drinks daily for men (1 drink = 5 oz wine, 12 oz beer, or 1.5 oz distilled spirits) in conjunction with your normal meal plan.
Avoid drinking alcohol on an empty stomach or following exercise, as it may increase the risk of hypoglycemia.
It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Moderate:
sevabertinib Food/Lifestyle
Applies to: sevabertinib
Grapefruit juice can increase the blood levels of sevabertinib. This may increase the frequency and/or severity of side effects such as diarrhea and lung (e.G., shortness of breath or trouble breathing, cough, or fever), liver, and eye (e.G., blurred vision, eye pain) problems.
You should avoid the consumption of foods or drinks containing grapefruit during treatment with sevabertinib.
Talk to your doctor or pharmacist if you have questions on how to take this or other medications you are prescribed. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Disease interactions
6 potential interactions Applies to: 5 conditions, including Pancreatitis, Liver Disease, Interstitial Lung Disease, Visual Defect/Disturbance, and Renal Dysfunction.
Interstitial Lung Disease
Moderate:
sevabertinib
Sevabertinib has a moderate potential interaction with Interstitial Lung Disease.
Sevabertinib can cause severe interstitial lung disease (ILD)/pneumonitis. Monitor patients for new or worsening symptoms such as dyspnea, cough, or fever, and discontinue sevabertinib if ILD/pneumonitis is confirmed.
Liver Disease
Moderate:
sevabertinib
Sevabertinib has a moderate potential interaction with Liver Disease.
The effect of moderate to severe liver dysfunction on the pharmacokinetics of sevabertinib is unknown. However, sevabertinib may cause severe hepatotoxicity and liver function should be monitored at baseline and regularly during therapy.
Pancreatitis
Moderate:
saxagliptin
sAXagliptin has a moderate potential interaction with Pancreatitis.
There have been postmarketing reports of acute pancreatitis in patients taking DPP-4 inhibitors. These drugs should be used with caution in patients with a history of pancreatitis or pancreatic disease, although it is unknown if they are at increased risk. Patients should be observed for signs and symptoms of pancreatitis during treatment. If pancreatitis is suspected, treatment should be discontinued immediately and appropriate management should be initiated.
Renal Dysfunction
Moderate:
saxagliptin
sAXagliptin has a moderate potential interaction with Renal Dysfunction.
It is recommended to assess renal function prior to initiating treatment with DPP-4 inhibitors and periodically thereafter. Patients with moderate to severe renal insufficiency and end stage renal dysfunction will require a dose adjustment. Linagliptin will not require a dose adjustment per manufacturer's information. Additionally, there have been postmarketing reports of worsening renal function in some patients with renal insufficiency taking sitagliptin at inappropriate doses.
Moderate:
sevabertinib
Sevabertinib has a moderate potential interaction with Renal Dysfunction.
The effect of severe renal dysfunction or end-stage renal disease on the pharmacokinetics of sevabertinib is unknown.
Visual Defect/Disturbance
Moderate:
sevabertinib
Sevabertinib has a moderate potential interaction with Visual Defect/Disturbance.
Sevabertinib may cause ocular toxicity. Promptly refer patients with new or worsening eye symptoms to an ophthalmologist and adjust therapy as recommended based on severity.
Report options
More resources
saxagliptin
A total of 473 drugs are known to interact with saxagliptin.
- Saxagliptin is in the drug class dipeptidyl peptidase 4 inhibitors.
- Saxagliptin is used to treat Type 2 Diabetes.
sevabertinib
A total of 473 drugs are known to interact with sevabertinib.
- Sevabertinib is in the drug class HER2 inhibitors.
- Sevabertinib is used to treat Non Small Cell Lung Cancer.
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.